{"classes":[{"categories":[{"measurements":[{"comment":"Upper limit is not estimable","groupId":"OG000","lowerLimit":"1.65","upperLimit":"NA","value":"3.22"},{"comment":"There was only one BAT patient responder (≥ 35% reduction in spleen volume) but no consecutive readings to determine any value for duration of response - no Median or CI possible to calculate","groupId":"OG001","lowerLimit":"NA","upperLimit":"NA","value":"NA"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"78"},{"groupId":"OG001","value":"1"}],"units":"Participants"}],"description":"DoMSR is defined as the interval between the first spleen volume measurement that is \\>=35% reduction from baseline and the first scan that is no longer = 35% reduction AND that is a \\>25% increase over nadir. It was evaluated using the Kaplan-Meier estimate for each treatment arm. The analysis was performed only for subjects who achieved greater than 35% reduction in spleen volume.","dispersionType":"95% Confidence Interval","groups":[{"description":"5 milligram tablets administered orally in an outpatient setting according to the protocol-specified dosing schedule","id":"OG000","title":"Ruxolitinib"},{"description":"Commercially available therapy, oral or parenteral, per manufacturer's instructions and Investigator discretion. BAT included the option of no treatment.","id":"OG001","title":"Best Available Therapy (BAT)"}],"paramType":"MEDIAN","populationDescription":"Full analysis set (FAS) consisted of all subjects who were randomized and put in strata according to International Working Group for Myelofibrosis Research and Treatment(IWG MRT) prognostic criteria. Treatment groups were defined according to the treatment assignment at the time of randomization.","reportingStatus":"POSTED","timeFrame":"Baseline, up to Year 5","title":"Duration of Maintenance of Spleen Volume Reduction (Median)","type":"SECONDARY","unitOfMeasure":"years"}